The JVs will do nothing to assist the cash flow situation? Everything depends on the science IMO and if the science is sound, and IMO it is, then the rest will follow. It's ridiculous to worry about CRs on the Nasdaq up to 2022 when there are JVs being negotiated.
Plus there is possible fast tracking for stage 3 acceptances of CHF and disc repair....if overwhelming efficacy. Safety is already proven.
They have a program they want to roll out. A lot of applications. They could pull back on that but why would they do that when they are proving the science? We just need partners and Celgene has extended their option to other applications under consideration.
One big ann with a big pharma and the situation changes.
Macquarie $1.33 Value Price, page-60
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |